Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

10:32 EDT 19th April 2014 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 15,000+

Extremely Relevant

Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway

[News] NICE guidance on aflibercept for treatment of metastatic colorectal cancer

On March 25, 2014, the National Institute for Health and Care Excellence (NICE) published guidance that did not recommend aflibercept with irinotecan and fluorouracil-based therapy (hereafter termed aflibercept) for treatment of metastatic colorectal...

Aveo slips on tivozanib update in colorectal cancer

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) said a planned interim analysis of the Phase II BATON-CRC trial showed first-line treatment with tivozanib plus chemotherapy is unlikely to meet the primary endpoint of improving progression-free survival (PFS)...

Important facts about colorectal cancer

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

Microbes in gut may increase risk for colorectal cancer

In one of the largest epidemiological studies of human gut bacteria and colorectal cancer ever conducted, a team of researchers at NYU Langone Medical Center has found a clear association between gut bacteria and colorectal cancer. The study, publish...

Lung Cancer Mutations Also Drive Colorectal Cancer

In results presented at ASCO 2013, a University of Colorado Cancer Center study shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. Results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.  Read more

Gut microbes may be a risk factor for colorectal cancer

(NYU Langone Medical Center / New York University School of Medicine) In one of the largest epidemiological studies of human gut bacteria and colorectal cancer ever conducted, a team of researchers at NYU Langone Medical Center has found a clear asso...

Known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These...

New Regimen for Elderly Patients With mCRC

Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer. Medscape Oncology

NYU Langone Medical Center researchers find link between gut bacteria and colorectal cancer

In one of the largest epidemiological studies of human gut bacteria and colorectal cancer ever conducted, a team of researchers at NYU Langone Medical Center has found a clear association between gut bacteria and colorectal cancer. The study, publish...

Gut Bacteria Linked With Colorectal Cancer In New Study

Scientists may have identified an important new factor in determining colorectal cancer risk -- and it lies in the gut. People with colorectal cancer may have fewer "good" bacteria and more harmful bacteria in their guts than people without...

Researchers discover promising new approach for colorectal cancer treatment

Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment...

Relevant

Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These...

[News] Bevacizumab for advanced cervical cancer

Addition of bevacizumab to chemotherapy increases overall survival in advanced cervical cancer that is not curable with existing standard therapy, according to a new study.

Gut microbes may play a role in colorectal cancer

New research from the US suggests an individual's particular mix of gut microbes may help the development of colorectal cancer tumors by interacting with genes and inflammatory responses.Colorectal cancer happens because healthy cells in the gut star...

March Is National Colorectal Cancer Awareness Month

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of colorectal cancer programs for national colorectal cancer awareness month. As the month of March brings colorectal cancer into focus, it’s time to increase publi...

NICE issues final no for Sanofi's Zaltrap

NICE assessed Zaltrap in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. The institute, which conducts health technolog...

Likely key driver of colorectal cancer development, progression

A molecule that is a probable driving force in colorectal cancer has been identified in a new study. The molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression. The researchers demonstrate...

Bevacizumab Bombs Again in the BETH Breast Cancer Study

With 2 different chemotherapy regimens, the addition of bevacizumab added no benefit and more adverse events. Medscape Medical News

Genetically targeted drugs used for lung cancer may also have applications in colorectal cancer patients

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These...

Online colorectal cancer risk calculator created

Researchers at Cleveland Clinic have developed a new tool called CRC-PRO that allows physicians to quickly and accurately predict an individual's risk of colorectal cancer, as published in the current edition of the Journal of the American Board of F...

Bevacizumab available for women on England’s cancer drugs fund

Women with advanced cervical cancer can now benefit from the drug bevacizumab, after the medicine was added to the cancer drugs fund today. Bevacizumab (Avastin; Roche) is currently used to treat a number of other cancers, including advanced bowe...

Study finds known lung cancer oncogenes also drive colorectal cancer

A study shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset...

Colorectal cancer: the risk factors, symptoms and importance of screening

According to the American Cancer Society, the lifetime risk of developing colorectal cancer is around 1 in 20. But according to a recent report from the Centers for Disease Control and Prevention, there are more than 20 million adults in the US who h...

Targeted therapies: Further delineating bevacizumab's response spectrum

The use of antiangiogenic drugs, such as bevacizumab, represents an appealing intervention against cancer. However, not all malignancies are equally responsive to such treatment. Recent trials demonstrate the efficacy of this drug for advanced-stage...


Search BioPortfolio:
Advertisement

News Quicklinks

Advertisement